2013
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis
Bignotti E, Tassi RA, Calza S, Ravaggi A, Rossi E, Donzelli C, Todeschini P, Romani C, Bandiera E, Zanotti L, Carnazza M, Quadraro F, Tognon G, Sartori E, Pecorelli S, Roque DM, Santin AD. Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. Journal Of Translational Medicine 2013, 11: 162. PMID: 23819652, PMCID: PMC3706350, DOI: 10.1186/1479-5876-11-162.Peer-Reviewed Original ResearchConceptsOvarian carcinomaNormal ovariesMammaglobin APrognostic markerLipophilin ALipophilin BPatients' clinico-pathological featuresMultivariate Cox regression analysisMammaglobin B mRNANeoplastic ovarian tissuesProgression-free survivalDisease-free survivalProtein expressionCox regression analysisLow tumor gradeClinico-pathological featuresIndependent prognostic markerUnivariate survival analysisOvarian carcinoma samplesAggressive tumor phenotypeGene overexpressionParaffin-embedded tumorsConclusionsThe present studyReal-time reverse transcription PCRQuantitative real-time reverse transcription PCR
2012
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma
Bignotti E, Zanotti L, Calza S, Falchetti M, Lonardi S, Ravaggi A, Romani C, Todeschini P, Bandiera E, Tassi RA, Facchetti F, Sartori E, Pecorelli S, Roque DM, Santin AD. Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. BMC Clinical Pathology 2012, 12: 22. PMID: 23151048, PMCID: PMC3534488, DOI: 10.1186/1472-6890-12-22.Peer-Reviewed Original ResearchDisease-free survivalEndometrioid endometrial carcinomaTrop-2 overexpressionProgression-free survivalIndependent prognostic factorHigh tumor gradePrognostic factorsEndometrial carcinomaTumor gradeMultivariate analysisTrop-2 protein expressionPoor disease-free survivalReduced disease-free survivalProtein expressionAdvanced FIGO stageCommon gynecologic malignancyEndometrioid endometrial cancerLymphovascular space invasionProtein overexpressionParaffin-embedded specimensAggressive tumor phenotypeSurgical stagingCervical involvementMedical comorbiditiesEndometrial cancerPrognostic factors and treatment-related outcomes in patients with uterine serous cancer (USC).
deLeon M, Lu L, Hui P, Santin A, Rutherford T, Arin-Silasi D, Azodi M, Ratner E, Schwartz P. Prognostic factors and treatment-related outcomes in patients with uterine serous cancer (USC). Journal Of Clinical Oncology 2012, 30: 5099-5099. DOI: 10.1200/jco.2012.30.15_suppl.5099.Peer-Reviewed Original ResearchStage IA/IBDisease-free survivalUterine serous cancerIIIA/IIIBIVA/IVBIA/IBUSC patientsPrognostic factorsMyometrial invasionLargest single-institution experienceWhole-pelvis radiation therapyLymph node involvementPlatinum-based chemotherapySingle institution experienceIndependent prognostic factorLymph node metastasisTreatment-related outcomesUterine cancer deathsBetter OSII-IVBIB diseaseNode involvementSurgical debulkingSerous cancerShorter OS
2009
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence
Tassi RA, Calza S, Ravaggi A, Bignotti E, Odicino FE, Tognon G, Donzelli C, Falchetti M, Rossi E, Todeschini P, Romani C, Bandiera E, Zanotti L, Pecorelli S, Santin AD. Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence. BMC Cancer 2009, 9: 253. PMID: 19635143, PMCID: PMC2724548, DOI: 10.1186/1471-2407-9-253.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOvarian cancerEOC patientsMammaglobin BFresh-frozen tissue biopsiesMultiple histological subtypesDisease-free survivalLong-term prognosisAdditional prognostic informationRisk of recurrenceIndependent prognostic markerIndependent prognostic valueProtein levelsUnivariate survival analysisCancer-related deathAggressive tumor behaviorNormal ovarian controlsPrimary surgeryClinicopathologic characteristicsDisease recurrencePrognostic factorsClinical outcomesClinicopathologic featuresDecreased riskHistological subtypes